General procedure VII -Cleavage of side-chain protected peptides from TCP-resin by acetic acid:
The swollen resin was washed 3 times with DCM. Then, a DCM/AcOH/TFE (7:2:1, v/v/v) mixture (8 mL/g resin) was added to the resin. After rotating for 30 min, the mixture was collected in a round bottom flask and the procedure repeated twice. The resin was washed with DCM (3×) and the washing solution was added to the flask. The mixture was concentrated in vacuo and the acetic acid co-evaporated by addition of toluene. The crude product was dissolved in a mixture of MeCN/H 2 O, lyophilized, and used without further purification.
General procedure VIII -Cleavage of side-chain protected peptides from TCP resin by HFIP:
A solution of 20% HFIP in DCM (v/v) was added to the resin-bound peptide and rotated for 20 min (8 mL/g resin). The procedure was repeated twice and the resin-bound peptide was washed with DCM (3 × 8 mL). The collected solutions were concentrated in vacuo and the crude product purified by RP-HPLC.
General procedure IX -Peptide backbone cyclization in solution using HATU/HOBt:
The linear, side-chain protected peptide was diluted in DMF to a concentration of 1 mM. After addition of HATU (2.0 equiv.), HOBt (2.0 equiv.) and DIEA (10.0 equiv.), the mixture was stirred for 12 h. The solvent was removed under reduced pressure and the cyclic peptide precipitated by addition of water. The peptide was spun down in a centrifuge, washed twice with water, and dried in a desiccator.
General procedure X -Removal of Bz/Cbz protecting group:
The peptide was dissolved in DMA and 100 mg/mol catalyst (10% Pd/C) was added to the solution. The flask was flushed with hydrogen and the solution stirred at ambient temperature and 1 bar H 2 pressure for 12 h. The solvent was removed in vacuo and the remaining solid redissolved in a mixture of MeCN/H 2 O (9:1). The catalyst was filtered off through Celite ® and the peptide obtained by lyophilization.
General procedure XI -Ligation of peptides using click-chemistry: Alkyne peptide (1.0 equiv.) and azide peptide (1.0 equiv. per alkyne moiety) were dissolved separately in a mixture of warm t BuOH/H 2 O (1:1 -2:1). 1.0 equiv. (referring to the alkyne) of an aqueous 0.1 M CuSO 4 solution was added. The flask was flushed thoroughly with argon. 2.0 equiv. (referring to the azide) of freshly prepared aqueous 0.1 M sodium ascorbate solution was added to the mixture under argon flow. The flask was sealed, equipped with a pressure outlet, heated to 70 °C and stirred for 3 h. The solvent was removed by freeze-drying after completion of the reaction and the crude product purified by RP-HPLC.
General procedure XII -Anchor modification of peptides:
The spacer peptide (1.0 equiv.) was dissolved in DMF and HATU (1.0 equiv. each). HOAt (1.0 equiv.) was added along with DIEA (4.0 equiv.). After stirring the solution at ambient temperature for 1 h, the corresponding amino functionalized molecule was added to the mixture and stirred for one additional hour. The solvent was evaporated and the crude product purified by RP-HPLC.
General procedure XIII -Full deprotection of cyclic peptides:
The protected, cyclic peptide was treated with a mixture of TFA, water and TIPS (95:2.5:2.5, v/v/v) for 1 h. The deprotected peptide was precipitated by addition to cold diethylether and spun down in a centrifuge. The precipitated peptide was washed twice with cold diethylether, dried under vacuum, and purified by RP-HPLC. 12.6 min.
Compound
11 2-Azidoethylamine: 2-Bromoethylamine hydrochloride (10.0 g, 48.8 mmol, 1.0 equiv.) was dissolved in 30 mL H 2 O. NaN 3 (9.5 g, 146.4 mmol, 3.0 equiv.) was added and the solution stirred at 75 °C for 18 h. NaOH (1.9 g, 48.8 mmol, 1.0 equiv.) was added slowly under stirring, the aqueous phase extracted with DCM (3 × 50 mL), the organic phase dried by MgSO 4 , and the solvent removed in vacuo to give a pale yellow, oily product (3.7 g, 42.6 mmol, 87%). Note, the product evaporates if the pressure is reduced below 80 mbar at a heating bath temperature of 40 °C. 12 2-(Tritylthio)ethylamine hydrochloride: 2-Aminoethylthiol (3.0 g, 38.9 mmol, 1.4 equiv.) and triphenylmethanol (7.23 g, 27.8 mmol, 1.0 equiv.) were dissolved in 50 mL TFA and stirred for 15 min. The solvent was removed in vacuo and the residue redissolved in ethyl acetate (180 mL), being extracted by sat. NaHCO 3 (3 × 100 mL) and dried by MgSO 4 . 30 g silica gel was added after filtration and the solvent removed in vacuo. The product was purified of triphenylmethanol by column chromatography, using an eluent mixture of hexane/ ethyl acetate = 9:1. The product was eluted from the column by chloroform/methanol (4:1) and the solvent removed in vacuo. The residue was redissolved in tert.-butanol and acidified through the addition of 1N HCl down to a pH of 1.5. The mixture was freeze dried to yield the final product (6.94 g, 19.5 mmol, 70% 15 1, 16 1, 12, 15, 18, 21, 5, 1, 12, 15, 18, 21, 24, 31, 34, 37, 40, 43, 
Ac-K[PPPPPP(5-hexynoic acid)]-OH:
The peptide was synthesized using the same methodology as described for 8 (107 mg, 0.12 mmol, 52% 
(5-hexynoic acid)PPP-K[PPP(5-hexynoic acid)]-OH:
The peptide was synthesized using the same methodology as described for 8, except for the following modifications: after initial Fmoc removal (General procedure II) from the Fmoc-Lys(Alloc)-OH loaded TCP resin, the first polyproline spacer moiety was synthesized by repetitive steps of General procedure II and General procedure IV. Synthesis was continued as described for 8 (213 mg, 0.23 mmol, 38% 
(5-hexynoic acid)PPPPPP-K[PPPPPP(5-hexynoic acid)]-OH:
The peptide was synthesized using the same methodology as described for 11 (324 mg, 0.22 mmol, 37% 
Immunofluorescence Staining
After 4 h on the nanopatterned surfaces, REF52 WT cells were washed with PBS at 37 °C and fixed with 2.5% paraformaldehyde in PBS for 10 min. Cells were then permeabilized with 0.1% Triton X-100 in PBS, blocked with 5% goat serum (Invitrogen, Germany) in PBS for 1 h at room temperature and incubated with 1:100 dilution of rabbit anti-paxillin (Abcam, USA) for 1 h at room temperature. Cells were labeled with 1:100 dilution of anti-rabbit Alexa 594-conjugated secondary antibody (Invitrogen, Germany) in 5% goat serum in PBS for 1 h at room temperature. Filamentous actin, membrane and nuclei were labeled with Alexa 488-conjugated phalloidin, Alexa 647-conjugated WGA and DAPI (Invitrogen, Germany), respectively. Cells were examined with a 63/1.25 Oil Ph3 Antiflex Plan-Neofluar objective (Carl Zeiss, Germany) using an Axiovert 200 fluorescent microscope (Carl Zeiss, Germany) equipped with a Hamamatsu (model C10600-10B-H) digital CCD camera (Hamamatsu Photonics, Germany). Image processing was achieved with the Axiovision Image viewer (Carl Zeiss, Germany). FA and Cell area analysis was performed on the 594 and 647 nm channels (16-bit TIF images), respectively, using the image analysis platform WiSoft TM (Idea Bio-Medical, Israel) . Briefly, images were first subjected to a low-pass filtration to smooth non-uniformities in intensity and secondly to a high-pass filtration to flatten the image and enhance edges. Finally, the resulting processed images were employed to tune the parameters (threshold, maximum and minimum size of the patches, etc.) for the segmentation module, which defines objects based on their intensity and morphological attributes. For each c(-RGDfX-)-based compound at least 50 cells from at least two independent experiments were evaluated. 
Electrochemical Experiments
SAMs of the different thiol-based cRGD peptides were prepared on flamed annealed gold substrates (Arrandees TM , Germany) by immersing the substrates into freshly prepared 50 µM solutions in MilliQ water for 2 h at ca. 22 °C. Afterwards, substrates were exhaustively rinsed with MilliQ water, dried under a stream of nitrogen and mounted in a conventional three-electrode electrochemical cell equipped with a Ag/AgCl reference electrode and a platinum mesh counter electrode. Reductive electrodesorption of thiols from the gold substrates was performed with an Autolab PGSTAT302N potentiostat (Echo Chemie, Germany) by scanning the potential from -0.6 to -1.3 V at 0.025 V/s in deaerated 0.05 M NaOH aqueous solution at ca. 22 °C. The cathodic peaks in the curves corresponds to the reductive desorption of thiol species from the gold surface, according to reaction: RS-Au + e -→ RS -+ Au. [2] The charge density was measured by integration of the current peaks and referred to the real surface area of the gold substrate to estimate the thiolate coverage according to Γ = Q/nFA, where Q is the charge under the reductive peak, n is the number of electrons involved in the reductive process, F is the Faraday constant and A the electroactive area. Immediately after desorbing the thiol monolayer, the working electrode was subjected to a linear sweep from -1.0 to 0.75 V at 0.025 V/s in the same electrolyte solution under the same geometrical configuration of the electrochemical cell. The real area of the gold surface was calculated by measuring the charge related to the AuO → Au phase change, i.e., the electroreduction charge, considering that 450 µC correspond to 1 cm 2 . [3] Average data presented in this work correspond to at least three measurements of the corresponding SAM. 
Quartz Crystal Microbalance with Dissipation (QCM-D)
The QCM-D measurements were carried out at 21 °C using a Q-Sense E4 microbalance (Q-Sense, Göteborg, Sweden). This instrument allows for a simultaneous measurement of frequency change (Δf) and energy dissipation change (ΔD) by periodically switching off the driving power of the oscillation of the sensor crystal and by recording the decay of the damped oscillation. The time constant of the decay is inversely proportional to D, and the period of the decaying signal gives f. Experiments were performed on gold-coated quartz crystals (QSX-301, Q-Sense) functionalized with an aqueous 50 µM solution of the corresponding cRGD peptide during 2 h at ca. 22 °C. Typically, after placing the cRGD-functionalized crystal into the QCM chamber, the baseline was established by flowing buffer solution (Tris-HCl 20 mM pH 7.4, NaCl 150 mM, MgCl 2 .6H 2 O 1 mM, CaCl 2 .2H 2 O 1 mM, MnCl 2 .2H 2 O 1 mM) at 50 µL/min during ca. 15 min. Afterwards, a solution of human integrin αvβ3 (Millipore, Schwalbach/Ts., Germany) 4 µg/mL prepared in the same buffer solution was injected. The flow was stopped ca. 10 min after integrin injection and the protein was left to interact with the surface for another 25 min. Finally, unbound protein was removed by rinsing the surface with buffer. The changes in the dissipation and normalized frequency, Δf = Δf n /n, correspond to the overtone number n = 3. The adsorption behavior of integrin αvβ3 on gold-coated quartz crystals functionalized with cRGD peptides was followed by QCM-D measurements. QCM crystals were modified with compound 7 and a mixed SAM composed of compound 7 and a non-functionalized Pro3-SH spacer and exposed to integrin solution. Compound 2 was selected as a reference since its use as coating for αvβ3 integrin-mediated cell adhesion has been studied extensively over the last years.
[4] Figure S5 shows the frequency shifts obtained for the different cRGD coatings. The highest binding was observed for the case of the mixed SAM followed by the coating made with pure compound 7, while QCM crystals functionalized with compound 2 exhibited a significantly lower frequency shift upon integrin binding. These results can be ascribed to the nature of the cRGD presentation at the surface. A close packed film, such as that obtained with compound 2 (see Table 2 of the manuscript), is likely to display a smaller free volume associated with each cRGD group, which restricts the ability of the protein to approach and bind to the epitope. [5] Conversely, the higher binding displayed by the surface coated with compound 7 can be associated with the more loosely packed nature of this film and the consequent greater free volume of each binding site. This effect was even more pronounced by diluting compound 7 with a non-functionalized Pro3-SH spacer. Clearly, increasing the length of the spacer and reducing the density of the binding site in the film had a positive impact on binding of integrin αvβ3 to the surface. In that scenario, the cRGD moieties can stand further away from each other and from the surface, thus sensitively decreasing the steric hindrance.
